(Q36294091)

13 August 2017

1 reference

title

Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development (English)

1 reference

13 August 2017

1 reference

Steven Whitebread

1

1 reference

13 August 2017

Jacques Hamon

series ordinal

2

1 reference

13 August 2017

Dejan Bojanic

series ordinal

3

1 reference

13 August 2017

Laszlo Urban

series ordinal

4

1 reference

13 August 2017

publication date

1 November 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

10

1 reference

13 August 2017

issue

21

1 reference

13 August 2017

page(s)

1421-1433

1 reference

Can the pharmaceutical industry reduce attrition rates?

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

New preclinical guidelines on drug effects on ventricular repolarization: safety pharmacology comes of age.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

The role of pharmacological profiling in safety assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Seven-transmembrane-spanning receptors and heart function

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

An EU perspective on the use of in vitro methods in regulatory pharmaceutical toxicology

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Phenytoin-loading: pharmacokinetic comparison between an intravenous bolus injection and a diluted standard solution

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Predicting undesirable drug interactions with promiscuous proteins in silico

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Pharmacogenomics of adrenoceptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Classification and nomenclature of 5-HT receptors: a comment on current issues

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Physiological roles of neuronal nicotinic receptor subtypes: new insights on the nicotinic modulation of neurotransmitter release, synaptic transmission and plasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Torsadogenic cardiotoxicity of antipsychotic drugs: a structural feature, potentially involved in the interaction with cardiac HERG potassium channels

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Integrating virtual screening in lead discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

A Potent Nonpeptide Antagonist of the Substance P (NK 1 ) Receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Induction of drug metabolism: the role of nuclear receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

A nuclear receptor-mediated xenobiotic response and its implication in drug metabolism and host protection.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Emerging safety issues regarding long-term usage of H(1)receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

H1-Antihistamines: more relevant than ever in the treatment of allergic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Cardiac actions of antihistamines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Non-cardiac adverse effects of antihistamines (H1-receptor antagonists).

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen derivatives as neuropeptide Y Y5 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Reduced food intake in response to CGP 71683A may be due to mechanisms other than NPY Y5 receptor blockade

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Modulation of feeding by hypothalamic paraventricular nucleus alpha 1- and alpha 2-adrenergic receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

The effect of hypothalamic peptide YY on hippocampal acetylcholine release in vivo: implications for limbic function in binge-eating behavior.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

B1 and B2 kinin receptors in various species

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Does potency predict clinical efficacy? Illustration through an antihistamine model

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Comparison of knowledge-based and distance geometry approaches for generation of molecular conformations

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Evolutionary optimization in quantitative structure-activity relationship: an application of genetic neural networks

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Neighborhood behavior: a useful concept for validation of "molecular diversity" descriptors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Caco-2 monolayers in experimental and theoretical predictions of drug transport

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib).

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Risk of cardiovascular events associated with selective COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

IKr channel blockers: novel antiarrhythmic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

Drug design strategies for targeting G-protein-coupled receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903632-9

7 January 2021

10.1016/S1359-6446(05)03632-9

Identifiers

DOI

1 reference

13 August 2017

1 reference